Xiaobei Dong1, Chi Chun Steve Tsang1, Shirong Zhao1, Jamie A Browning1, Jim Y Wan2, Marie A Chisholm-Burns1, Christopher K Finch1, Jack W Tsao3, Lisa E Hines4, Junling Wang1. 1. Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA. 2. Department of Preventive Medicine, University of Tennessee Health Science Center College of Medicine, Memphis, TN, USA. 3. Department of Neurology, University of Tennessee Health Science Center & Children's Foundation Research Institute, Le Bonheur Children's Hospital, Memphis, TN, USA. 4. Performance Measurement, Pharmacy Quality Alliance, Alexandria, VA, USA.
Abstract
OBJECTIVE: Older patients with Alzheimer's disease (AD) are challenged with adhering to complex medication regimens. We examined effects of Comprehensive Medication Review (CMR), a required Medicare Part D Medication Therapy Management (MTM) program component, on medication adherence among AD patients. METHODS: This retrospective study analyzed 100% of 2016-2017 Medicare claims covering the entire United States, linked to Area Health Resources Files. Medicare beneficiaries aged ≥65 years were included. Propensity score matching identified comparable intervention and comparison groups with the intervention defined as receiving a CMR in 2017. A difference-in-differences analysis included in multivariate logistic regressions an interaction term between CMR receipt and year 2017. The outcome measured was nonadherence to diabetes, hypertension and hyperlipidemia medications, with nonadherence defined as proportion of days covered <80% for study medications. RESULTS: Unadjusted comparisons indicated the proportion of nonadherence for intervention group members decreased from 2016 to 2017 but increased for the comparison group. In adjusted analyses, reduction in medication nonadherence among the intervention group remained higher: odds ratios for the interaction term were 0.62 (95% confidence interval [CI] = 0.54-0.71), 0.54 (95% CI = 0.50-0.58) and 0.50 (95% CI = 0.47-0.53) respectively for diabetes, hypertension and hyperlipidemia medications. This suggests that the likelihood of nonadherence in the intervention group was respectively reduced by 38%, 46% and 50% more than the comparison group. CONCLUSIONS: CMR was found to reduce nonadherence to diabetes, hypertension and hyperlipidemia medications among older Medicare beneficiaries with AD. This provides evidence that the MTM program is effective for a population with unique medication compliance challenges.
OBJECTIVE: Older patients with Alzheimer's disease (AD) are challenged with adhering to complex medication regimens. We examined effects of Comprehensive Medication Review (CMR), a required Medicare Part D Medication Therapy Management (MTM) program component, on medication adherence among AD patients. METHODS: This retrospective study analyzed 100% of 2016-2017 Medicare claims covering the entire United States, linked to Area Health Resources Files. Medicare beneficiaries aged ≥65 years were included. Propensity score matching identified comparable intervention and comparison groups with the intervention defined as receiving a CMR in 2017. A difference-in-differences analysis included in multivariate logistic regressions an interaction term between CMR receipt and year 2017. The outcome measured was nonadherence to diabetes, hypertension and hyperlipidemia medications, with nonadherence defined as proportion of days covered <80% for study medications. RESULTS: Unadjusted comparisons indicated the proportion of nonadherence for intervention group members decreased from 2016 to 2017 but increased for the comparison group. In adjusted analyses, reduction in medication nonadherence among the intervention group remained higher: odds ratios for the interaction term were 0.62 (95% confidence interval [CI] = 0.54-0.71), 0.54 (95% CI = 0.50-0.58) and 0.50 (95% CI = 0.47-0.53) respectively for diabetes, hypertension and hyperlipidemia medications. This suggests that the likelihood of nonadherence in the intervention group was respectively reduced by 38%, 46% and 50% more than the comparison group. CONCLUSIONS: CMR was found to reduce nonadherence to diabetes, hypertension and hyperlipidemia medications among older Medicare beneficiaries with AD. This provides evidence that the MTM program is effective for a population with unique medication compliance challenges.
Authors: Bruce Stuart; Franklin B Hendrick; Xian Shen; Mingliang Dai; Sarah E Tom; J Samantha Dougherty; Laura M Miller Journal: Health Aff (Millwood) Date: 2016-09-01 Impact factor: 6.301
Authors: Deborah L Pestka; Alan J Zillich; Antoinette B Coe; Karen B Farris; Omolola A Adeoye; Margie E Snyder; Joel F Farley Journal: J Am Pharm Assoc (2003) Date: 2020-01-08
Authors: Noll L Campbell; Anthony J Perkins; Sujuan Gao; Todd C Skaar; Lang Li; Hugh C Hendrie; Nicole Fowler; Christopher M Callahan; Malaz A Boustani Journal: J Am Geriatr Soc Date: 2017-03-14 Impact factor: 5.562
Authors: Jamie A Browning; Chi Chun Steve Tsang; Rose Zeng; Xiaobei Dong; Joseph Garuccio; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Junling Wang Journal: Curr Med Res Opin Date: 2022-08-09 Impact factor: 2.705